期刊文献+

秋水仙碱位点抑制剂的结构特征研究 被引量:6

Study on the structural features of colchicine-site inhibitors
下载PDF
导出
摘要 目的:寻找秋水仙碱结合位点抑制剂的结构特征。方法:将对接得到的8种不同结构抑制剂的结合构象进行叠合匹配,并结合已有的SAR结论来探讨。结果:整个结构由两个疏水基团A、B以及之间的桥链部分组成,但是在空间上A和B必须处于桥链的同侧。A基团的体积以及氢键受体基团的存在对活性有较大影响,B需为平面环且宜连接极性基团以增强结合,而桥链部分可以为1~4个长度的原子但以sp2杂化类型最佳。结论:研究得出的结构特征为设计新的秋水仙碱位点抑制剂提供了直观、简便的参考。 Objective:To determine the structural features of a set of diverse colchicines-site inhibitors. Methods:The features were revealed by matching the binding conformations generated from docking studies of eight inhibitors, and combined with the available SAR results. Results: The feature is represented as two hydrophobic groups (A and B) and a bridge linked between them, but A and B should be in the same side of the bridge, The volume size and the existence of hydrogen-bond acceptor of group A may have some influence on binding. Group B should be a hydrophobic planar ring, and polar functional group is advantageous, The bridge part could accept 1 -4 atoms, but the Sp2 hybrid is welcome. Conclusion:this result may provide useful insights for the design of novel Colchicine-site inhibitors.
出处 《药学实践杂志》 CAS 2007年第6期372-375,共4页 Journal of Pharmaceutical Practice
关键词 微管 秋水仙碱 药效团 分子对接 microtubule colchicine pharmacophor molecular docking
  • 相关文献

参考文献15

  • 1Downing KH, Nogales E. Tubulin structure: insights into microtuhule properties and functions [ J ]. Curr Opin Struct Biol, 1998, 8(6) :785.
  • 2Tron, GC, Pirali T, Sorba G, et al. Medicinal chemistry of combretastatin A4: present and future directions[J]. J Med Chem, 2006, 49( 11 ) :3033.
  • 3Ozawa Y, Sugi NH, Nagasu T, et al. E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo[ J], Eur J Cancer, 2001, 37(17) :2275.
  • 4Wipf P, Reeves JT, Day BW. Chemistry and Biology of Curacin A[J]. Curr Pharm Design, 2004, 10(21):1417.
  • 5Nguyen TL, McGrath C, Hermone AR, et al. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach [J]. J Med Chem, 2005, 48( 19): 6107.
  • 6Gaukroger K, Hadfield JA, Lawrence NJ, et al. Structural re quirements for the interaction of combretastatins with tubulin how important is the trimethoxy unit[J]. Org Binmol Chem 2003, 1 ( 6 ) :3033.
  • 7Hamel E, Lin CM, Flynn E, et al. Interactions of 2-Methoxyestradiol, an endogenous mammalian metabolite, with unpo- lymerized tubulin and with tubulin pnlymers[J]. Biochemistry, 1996, 35(4) :1304.
  • 8Ducki S, Mackenzie G, Lawrence N J, et al. Quantitative structure-activity relationship (5D-QSAR) study of combretastatin- like analogues as inhibitors of tubulin assembly [J]. J Med Chem, 2005, 48(2) :457.
  • 9Pettit GR, Rhodes MR, Herald DL, et al. Synthesis and evaluation of structural modifications of (Z) - and (E)-combretastatin A-4[J]. J Med Chem, 2005, 48(12) :4087.
  • 10Pettit GR, Toki B, Herald DL, et al. Synthesis of phenstatin phosphate[J]. J Med Chem, 1998, 41(10):1688.

同被引文献173

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部